natalizumab · Tysabri
Monoclonal antibody
Also known as BG00002
Biosimilars tracked: Tyruko (natalizumab-sztn)
Evidence outlook
Approved: Multiple Sclerosis, Crohn's Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis
- TYSABRI (natalizumab) is indicated: • as monotherapy (i.e. single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis. Safety and efficacy in patients with chronic...
- Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00027300 NCT00027300 · Multiple Sclerosis, Relapsing-Remitting The trial was large, randomized, blinded, and placebo-controlled, with hard clinical endpoints of relapse rate and disability progression, and natalizumab significantly reduced both (68% relapse-rate reduction and 42% reduction in sustained disability progression, both P<0.001). Registry: NCT00027300 | 3 | The primary objectives of this study are to determine whether natalizumab, when compared with placebo, is effective in reducing the rate of clinical relapses at 1 year and, in slowing the progression of disability at 2 years. (1 year and 2 years) 2004-11 | Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001). | Reliable signal | link ↗ |
View 1 more trial
NCT03689972 NCT03689972 · Multiple Sclerosis, Relapsing-Remitting The study randomized 499 participants in Part 1 and 153 in the Part 2 crossover, but it was not blinded and compared different natalizumab dosing or administration schedules rather than placebo. Its primary outcomes included an MRI lesion-count measure and treatment preference, not a hard clinical endpoint; the Part 1 MRI comparison was not statistically significant (p=0.0755), and the Part 2 preference result was descriptive rather than a clearly significant comparative test. Registry: NCT03689972 | 3 | Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72; Part 2: Percentage of Participants Indicating a Preference for Natalizumab SC Administration at the End of Crossover Period of Part 2 (Week 150) 2023-01-31 | Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other α4 integrin drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Natalizumab (Tysabri): this drug | Approved | Monoclonal antibody | α4 integrin | Partial signal | NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide (Entocort EC) | Approved | Small molecule | Glucocorticoid receptor | Weak signal | Featured results are safety only in this race | |
| Budesonide (Ortikos) | ApprovedUS marketing discontinued | — | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34) | |
| Dexamethasone | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02). | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin | |
| Infliximab-Dyyb (Zymfentra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab) | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1)) | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD) NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | Reliable signal | NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w) NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg)) | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Vedolizumab (Entyvio) | Approved | Monoclonal antibody | α4β7 integrin | Partial signal | NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC) NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed | |
| Afimkibart | Phase 3 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Duvakitug | Phase 3 | Monoclonal antibody | TL1A | Partial signal | NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. | |
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Remestemcel-L (Ryoncil) | Phase 3 | Cell therapy | Allogeneic MSC therapy | Partial signal | No reviewed efficacy summary in this indication | |
| TH-SC01 | Phase 3 | Cell therapy | Mesenchymal stem cells (MSC) | Weak signal | No reviewed efficacy summary in this indication | |
| Tirzepatide (Zepbound) | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 3 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Icotrokinra (Icotyde) | Phase 2/3 | Peptide | IL-23 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Amiselimod | Phase 2 | Small molecule | S1P receptor | Partial signal | NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed | |
| AVB-114 | Phase 2 | Cell therapy | Implantable cell/biomaterial construct | Partial signal | NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29). | |
| AZD7798 | Phase 2 | Monoclonal antibody | CCR9 | Weak signal | Featured results are safety only in this race | |
| ExoFlo | Phase 2 | Cell therapy | MSC-derived exosomes | Weak signal | Featured results are safety only in this race | |
| Golimumab (Simponi) | Phase 2 | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| MT-201 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| MT-501 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Obefazimod | Phase 2 | Small molecule | miR-124 | not yet graded | No reviewed efficacy summary in this indication | |
| Omilancor | Phase 2 | Small molecule | LANCL2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zotemtegrast | Phase 2 | Small molecule | α4β7 integrin | not yet graded | No reviewed efficacy summary in this indication | |
| EcoActive | Phase 1/2 | Microbiome therapeutic | Bacteriophage (anti-AIEC) | not yet graded | No reviewed efficacy summary in this indication | |
| Furestem-CD | Phase 1/2 | Cell therapy | Allogeneic MSC therapy | Weak signal | No reviewed efficacy summary in this indication | |
| ICG318 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ALLO-ASC | Phase 1 | Cell therapy | Adipose-derived MSC therapy | Weak signal | No reviewed efficacy summary in this indication | |
| BDHK-2009 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Hemay007 | Phase 1 | Small molecule | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| HRS-7085 | Phase 1 | Small molecule | NCBP1/NCBP2 (nuclear cap-binding complex) | Weak signal | No reviewed efficacy summary in this indication | |
| Firategrast (SB-683699) | Discontinued | Small molecule | VLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4) | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 61 furthest-along competitors are listed; 10 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tysabri (natalizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.